Objective: The chemotherapeutic agent mitoxantrone was approved for use in multiple sclerosis (MS) in 2000. After a review of all the available evidence, the original report of the Therapeutics and Technology Assessment Subcommittee in 2003 concluded that mitoxantrone probably reduced clinical attack rates, MRI activity, and disease progression. Subsequent reports of decreased systolic function, heart failure, and leukemia prompted the US Food and Drug Administration to institute a "black box" warning in 2005. This review was undertaken to examine the available literature on the efficacy and safety of mitoxantrone use in patients with MS since the initial report.
Mitoxantrone hydrochloride (MX) (Novantrone ® , EMD Serono, Inc., Rockland, MA) is an anthracenedione initially developed as an antineoplastic agent. MX reduces lymphocyte proliferation through several mechanisms of action, including intercalation into DNA strands inducing strand breakage and inhibition of the DNA repair enzyme topoisomerase II.
1 On the basis of the European Mitoxantrone in Multiple Sclerosis Group (MIMS) phase III study, the final report of which was published in 2002, 2 the US Food and Drug Administration (FDA) extended approval for the treatment of aggressive relapsing-remitting multiple sclerosis (RRMS), secondary-progressive multiple sclerosis (SPMS), and progressive-relapsing multiple sclerosis in 2000. MX is usually given IV at a dose of 12 mg/m 2 every 3 months until a maximum cumulative lifetime dose of 140 mg/m 2 is reached. The Therapeutics and Technology Assessment (TTA) Subcommittee of the American Academy of Neurology (AAN) reviewed the literature on MX use in multiple
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Supplemental data at www.neurology.org sclerosis (MS) in 2003. 3 At that time, the TTA Subcommittee reached Level B recommendations that MX was probably effective in modestly reducing clinical attack rate, MRI activity, and disease progression. (The MIMS trial was considered to represent Class II/III evidence because of incomplete blinding.) The TTA also recommended that the results of the MIMS phase III study be replicated before widespread adoption of MX as a disease-modifying agent, given the potential for treatment-related acute leukemia (TRAL) and cardiotoxicity to outweigh the clinical benefits.
In March 2005, the FDA instituted changes to the MX product labeling, including a "black box" warning about cardiotoxicity and TRAL.
1 This warning was prompted by postmarketing reports of cardiotoxicity at cumulative doses Ͻ100 mg/m 2 as well as reports of TRAL. 4 Evaluation of left ventricular ejection fraction (LVEF) prior to initiating therapy and before each subsequent dose was advised. Previously, cardiac monitoring had only been recommended prior to therapy and after each infusion once a cumulative dose of Ն100 mg/m 2 had been reached. In July 2008, the FDA made the further recommendation that patients receive annual cardiac function testing after completing MX therapy because of the potential for delayed cardiotoxicity. The purpose of this update is to review the literature since the original TTA report, specifically focusing on the efficacy and safety of MX use in patients with MS.
DESCRIPTION OF THE ANALYTIC PROCESS
The OVID MEDLINE and the Cochrane Controlled Trials Database were searched using the keywords mitoxantrone and multiple sclerosis. All articles published in English before July 2009 with both of these terms were retrieved (i.e., only articles pertaining to MX use in MS were considered). Recently published articles were also sought through manual searches of neurology journals and reference lists of relevant publications. Abstracts from the AAN annual meetings and the European Committee for Treatment and Research in Multiple Sclerosis Annual Conferences from 2002 to 2009 were also manually reviewed for case reports of leukemia following MX therapy.
For assessment of efficacy, only controlled clinical trials or cohort studies (Class I and Class II evidence for therapeutic articles; see appendix e-3a on the Neurology ® Web site at www.neurology.org) with defined clinical or MRI endpoints published since the first TTA review were included in the analysis. For assessment of cardiotoxicity and TRAL, all published information, including case series or case reports and abstracts from poster or oral presentations, was reviewed (Class I-Class IV evidence for screening articles; see appendix e-3b).
A total of 434 articles and abstracts was retrieved through electronic searches and manual searching of abstracts and recent journal volumes. Seventeen efficacy studies published after the last TTA report were identified, including 2 Class I or II studies and 15 Class III or IV studies. Only the Class I and II studies were included in our evaluation. Eleven published Class III studies provided sufficient details to assess cardiotoxicity. TRAL was reported in 31 studies (including 4 poster/oral presentation abstracts), predominantly in small case series or individual case reports (Class III-IV).
ANALYSIS OF EVIDENCE Efficacy. No large-scale randomized controlled trial has replicated the MIMS study since the original TTA report. An MRI substudy of the MIMS trial did not show a benefit of MX on the primary endpoint (Class II evidence). 5 A trial designed to assess the safety of MX induction before glatiramer acetate monotherapy demonstrated a greater reduction in contrast-enhancing lesions in patients treated with MX over 15 months, although no effect on relapses or Expanded Disability Status Scale progression was detected (Class I evidence). 6 Therefore, the original recommendation remains Level B.
Safety. Cardiotoxicity. Cardiotoxicity (characterized by decreased LVEF and/or congestive heart failure [CHF]) is a well-documented complication of MX use in cancer. CHF develops in 2.6% of MX-treated patients with cancer.
1 As noted in the original TTA report on MX use in MS, 3 an early review of cardiotoxicity in MX-treated patients with MS was reported in 2002. 7 This report included information from the MIMS trial, 2 an open-label multicenter study from France, 8 and a cohort from a single German center. 9 Of the total 1,378 patients, 2 developed CHF. Follow-up LVEF assessments were performed in 779 patients; of these, 17 patients (2.2%) developed asymptomatic LVEF Ͻ50%.
Since the initial TTA review, a series of Class III studies documented cardiotoxicity in MX-treated patients with MS (table 1), although the reported frequency, severity, and time course of cardiac complications varies markedly. Early cardiotoxicity was reported in 2 Class III studies. 10, 11 In the first, LVEF decreased significantly in 5 out of 28 patients (ϳ18%) after 3 doses of MX (12 mg/m 2 every 3 months). 10 In the second study (n ϭ 18), 4 patients developed asymptomatic decreased LVEF after 1-2 MX infusions at cumulative doses ranging from 17.7 to 51.4 mg. 11 Four other patients showed evidence of isolated diastolic dysfunction. Follow-up echocardio-grams showed improvement of LVEF in all patients and 2 patients subsequently resumed MX therapy without further complications.
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Another Class III study of a 52-patient cohort reported late development of CHF in 3 patients between 24 and 80 months after discontinuation of MX. 12 One Class III study of 96 patients who received a cumulative dose of 48 mg/m 2 of MX over 1 year reported asymptomatic decreased LVEF in 6 patients. 13 Three of these patients had LVEF Ͻ50% at 6 months and discontinued therapy. In another Class III study of 48 patients with SPMS, 2 patients developed asymptomatic and partially reversible LVEF Ͻ40% after 1 year (48 mg/m 2 ) of MX. 14 A Class III study of 31 patients receiving 5 mg/m 2 of MX every 3 months reported asymptomatic LVEF Ͻ50% in 4 patients after Ն12 months of treatment. 15 One Class III study of 118 patients reported decreased LVEF Ͼ10% in 25 patients, LVEF Ͻ50% in 4 patients, and 1 myocardial infarction. 16 Another Class III study of 102 patients treated with a cumulative dose of 108 mg/m 2 reported asymptomatic decreased LVEF in 31 patients (30%). 17 Other Class III studies, however, have not demonstrated such high rates of cardiotoxicity. In one series of 73 patients, no cardiotoxicity was observed, although 2 patients receiving at least 4 doses of MX were lost to follow-up. 18 Similarly, in another Class III study of 50 prospectively assessed patients, no decrease in LVEF was seen during 2 years of therapy, although cardiac function was not assessed in 3 years of follow-up after discontinuation of MX. 19 A recent Class III study of 100 patients with aggressive RRMS receiving induction MX therapy noted asymptomatic worsening LVEF in 3 patients following MX therapy. 20 Consolidating these various reports provides an estimated 83/716 (ϳ12%) rate of decreased LVEF and 3/716 (ϳ0.4%) risk of CHF, although the differences in MX regimens and cardiac-monitoring protocols employed in the different centers make this composite figure only a general approximation. The number needed to harm (NNH) for left ventricular dysfunction is 8. This NNH means that for every 8 patients treated with MX, 1 patient will experience some degree of cardiotoxicity.
RENEW, a phase IV study of MX use, is ongoing. As of January 2008, CHF had developed in 2% of the observed 509 patients, according to the latest presented data. 21 Serial cardiac function results were available for 200 patients, of whom 26 (13%) had LVEF Ͻ50%.
The iron-chelator dexrazoxane was studied in MX-treated patients with MS to evaluate a mitigating effect on MX-induced cardiotoxicity. 22 The study was an open-label comparison of patients 
Abbreviations: AMI ϭ acute myocardial infarction; CHF ϭ congestive heart failure; LVEF ϭ left ventricular ejection fraction; MUGA ϭ multigated radionuclide angiography; MX ϭ mitoxantrone hydrochloride; TTE ϭ transthoracic echocardiogram. a See appendix e-3 for descriptions of classification of evidence. treated with (n ϭ 28) or without (n ϭ 19) dexrazoxane in conjunction with MX. While a blinded assessor evaluated LVEF using multiple gated acquisition scanning, the 2 arms were recruited separately (Class III). Both patient groups experienced significant decreases in LVEF at 1 year; however, the mean percent change was lower in the dexrazoxane-treated group (Ϫ3.8% compared with Ϫ8.6%; p Ͻ 0.001). Leukemia. TRAL is a recognized complication of chemotherapy. 23 Most cancer patients are treated with combinations of chemotherapeutic agents, including MX, and in this population TRAL occurs in 2%-12% of patients, with a median time of 22 months between onset of MX therapy and TRAL. 23, 24 The first case report of TRAL in a patient with MS was published in 1998. 25 An early review estimated that the risk of TRAL in the MS population was 0.07% after a mean follow-up of 36 months in 1,378 patients. 26 These data were based on the MIMS study 2 (124 patients) and the aforementioned multicenter French 8 (802 patients) and single-center German 9 studies (452 patients). No TRAL was seen in the MIMS or German cohorts, but one case was seen in the French study. The authors note in an addendum to the article that a second patient in the French cohort also developed TRAL, making the corrected rate 0.25% at 3.1 years in that 802-patient cohort, or 0.15% of the overall 1,378 patients (table 2) . 26 Subsequently, a number of Class III and IV case series and case reports have reported 56 -57 individual cases of TRAL in MX-treated patients with MS (table 2; one patient may be duplicated in references 29 and 38) . In contrast to the low incidence reported earlier, recent reports (3 as abstracts) have documented rates of TRAL between ϳ2% and 3%. [27] [28] [29] [30] [31] Additionally, in one of these cohorts, all 3 affected patients died despite adequate treatment, 28 in contrast to the majority of reported cases where leukemia remission was achieved following chemotherapy and/or bone marrow transplantation (see table 2 ). The majority of TRAL cases in the MS population occur within a few years of MX use, the original case report being an outlier at 5 years post-therapy (see table 2 ).
Other case series reported lower rates of TRAL. In a Class III retrospective study of 100 consecutive French patients who received induction monthly MX boluses for 6 months (max 72 mg/m 2 ), one patient (previously reported in a larger cohort 26 ) developed acute myelogenous leukemia. 20 A Class III retrospective survey of 304 patients treated at a single center in France 32 identified only one previously reported case of TRAL. 33 The latest presented update of the United States RENEW registry reported leu- kemia in 3/509 patients; however, only 2 were thought to be TRAL. 21 In addition, one case has recently been published of a patient developing chronic myeloid leukemia (CML) 16 months after MX therapy. 34 CML is not a recognized TRAL in either the cancer or MS population and it is unclear whether this malignancy resulted from the MX therapy.
Combining all of the reports listed in table 2 in which a denominator is available, the incidence of TRAL in patients with MS is 33/4,076 (ϳ0.81%). The NNH for the development of TRAL is 123. This figure is only an approximation, however, given the heterogeneity in the length of follow-up documented in the various case series. Nevertheless, this result is very similar to the findings of a recent large retrospective review from 35 Italian MS Centers that reported 21 cases of TRAL in 2,854 (0.74%) patients treated with MX (Class III). 35 These authors also demonstrated a strong doseresponse relationship, with the incidence rate ratio increasing from 1.84 at doses Յ60 mg/m 2 to 2.74 at doses Ն82.4 mg/m 2 . (It is unclear which of these 21 cases have been previously reported in the references listed in table 2.) Fifteen deaths occurred in the 51 patients (29%) whose outcome was reported; however, it is not known how many other patients in remission subsequently died.
Conclusions. While the Class III and IV evidence available provides conflicting estimates of both the frequency and severity of MX-related cardiotoxicity, asymptomatic decreased systolic function occurs in approximately 12% of patients treated with MX, and CHF occurs in approximately 0.4%. The literature on TRAL in MX-treated patients with MS is also limited to Class III and IV evidence; however, the cumulative incidence appears to be ϳ0.8%. Both TRAL and systolic dysfunction can occur at any time after initiation of MX, including early in the treatment course.
The evidence regarding toxicity suggests the risk of systolic dysfunction associated with the use of MX in patients with MS results in an NNH of 8, and the risk of TRAL with MX therapy results in an NNH of 123. This demonstrates that the risk of both cardiotoxicity and leukemia is likely higher than earlier estimates.
CLINICAL CONTEXT Recommendations on MX use reflecting the potential for harm would require a risk-benefit analysis and are beyond the scope of an evidence-based guideline. In the absence of such an analysis, it is reasonable for clinicians to follow the recommendations outlined in the product monograph and include ejection fraction assessments before initiating treatment and administering each dose of MX and yearly after discontinuation of treatment. It is not known whether patients treated with MX with asymptomatic decreased LVEF will experience long-term sequelae. The long-term sequelae of asymptomatic cardiotoxicity is not clear. It is reasonable for clinicians to monitor patients for TRAL after MX therapy with periodic complete blood cell counts, although the optimal timing of such monitoring is not known.
Clinicians contemplating MX administration for an individual patient with MS must weigh the potential for benefit against the potential for harm given the ϳ12% risk of systolic dysfunction and ϳ0.8% risk of TRAL and the availability of alternative therapies with less severe toxicities (e.g., interferon-␤ and glatiramer acetate) for patients with RRMS.
RECOMMENDATIONS FOR FUTURE RESEARCH
• The best evidence for MX use in MS remains the MIMS trial. The first report of the TTA in 2003 recommended that the results of this trial be replicated, and this has not occurred to date. No Class I evidence exists to support the use of MX in the MS population.
• Future trials using MX induction followed by standard disease-modifying agents should be considered. Any future trial should include a prospective, long-term safety analysis.
• While the rate of symptomatic cardiotoxicity and TRAL appears low, more reports are arising to suggest that these risks are higher than indicated by the initial evidence. It is imperative that longterm, prospective postmarketing data be compiled to better quantify the risks of MX therapy.
